Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Return on Equity (2018 - 2025)

Denali Therapeutics (DNLI) has disclosed Return on Equity for 8 consecutive years, with 0.53% as the latest value for Q4 2025.

  • Quarterly Return on Equity fell 20.0% to 0.53% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.53% through Dec 2025, down 20.0% year-over-year, with the annual reading at 0.46% for FY2025, 8.0% down from the prior year.
  • Return on Equity for Q4 2025 was 0.53% at Denali Therapeutics, down from 0.51% in the prior quarter.
  • The five-year high for Return on Equity was 0.05% in Q2 2021, with the low at 0.53% in Q4 2025.
  • Average Return on Equity over 5 years is 0.26%, with a median of 0.31% recorded in 2022.
  • The sharpest move saw Return on Equity surged 52bps in 2021, then tumbled -39bps in 2022.
  • Over 5 years, Return on Equity stood at 0.29% in 2021, then decreased by -20bps to 0.35% in 2022, then surged by 62bps to 0.14% in 2023, then crashed by -146bps to 0.33% in 2024, then tumbled by -59bps to 0.53% in 2025.
  • According to Business Quant data, Return on Equity over the past three periods came in at 0.53%, 0.51%, and 0.45% for Q4 2025, Q3 2025, and Q2 2025 respectively.